Upload
Featured Recent Articles Topics Login Upload

Search Results for ''

published presentations and documents on DocSlides.

Using Maslow’s Belonging Needs to design an anti-cancer p
Using Maslow’s Belonging Needs to design an anti-cancer p
by karlyn-bohler
MR. . AMERODEN DATUSOLAIMAN LAO . (PHILIPPINES). ...
Disrupting Cancer Care:
Disrupting Cancer Care:
by sherrill-nordquist
Novel Ways to Bend Cancer Spending Trend. . Mana...
A Recommendation of the Cancer Moonshot Blue Ribbon Panel
A Recommendation of the Cancer Moonshot Blue Ribbon Panel
by williams
IOTN THE IMMUNO-ONCOLOGY TRANSLATIONAL NETWORK Ad...
Course Proposal: Methods in Clinical Cancer Research
Course Proposal: Methods in Clinical Cancer Research
by white
. Primary Instructor: . Elizabeth Garrett-Mayer, P...
The Use of PARP Inhibitors in Breast Cancer: Challenges
The Use of PARP Inhibitors in Breast Cancer: Challenges
by calandra-battersby
and Opportunities. This program will include a di...
Manali Patel, MD, MPH Nothing to disclose
Manali Patel, MD, MPH Nothing to disclose
by elizabeth
Discussion of off-label drug use:. not applicable...
Engineering Design and Development
Engineering Design and Development
by tawny-fly
The Grand Challenges: Education, Energy, Environm...
Phase I and Phase II trial design in
Phase I and Phase II trial design in
by tatiana-dople
oncology. Shu-Fang Hsu Schmitz. University of Ber...
Introduction to Study Design
Introduction to Study Design
by molly
Rosie . Stanoev. , Master’s Student (Clinical Ep...
Biostatistics & Bioinformatics Shared Facility
Biostatistics & Bioinformatics Shared Facility
by elysha
Sejong Bae, PhD, FMSSANZ, . Young-il Kim, PhD . El...
Biomarkers in Phase II designs in cancer clinical trials
Biomarkers in Phase II designs in cancer clinical trials
by conchita-marotz
Methods in Clinical Cancer Research. February 12,...
http://www.cdc.gov/healthmarketing/resources.htm
http://www.cdc.gov/healthmarketing/resources.htm
by debby-jeon
Syllabus Discussion
Syllabus Discussion
by lindy-dunigan
Public Health Presentations. We are Engineering ....
Re -think,
Re -think,
by karlyn-bohler
Re. -generate, . Re. -. envisage. fashionable . s...
Design considerations for drug development in the era of immuno-oncology
Design considerations for drug development in the era of immuno-oncology
by isabella
Elizabeth Garrett-Mayer, PhD. Director, Division o...
Date of admission to hospital
Date of admission to hospital
by cadie
Day 0. Inclusion Assessment Window. Lab confirmed ...
Study Designs Objectives
Study Designs Objectives
by ida
To learn the common . study designs.. To learn the...
Mutations in MCL-1 PEST Region of Breast Cancer on Binding Affinity to
Mutations in MCL-1 PEST Region of Breast Cancer on Binding Affinity to
by madeline
Bak/Bax . Deeksha Jain. Cancer . Apoptosis + Regu...
A Bayesian Approach in Design and Analysis of Pediatric Cancer Clinical Trials
A Bayesian Approach in Design and Analysis of Pediatric Cancer Clinical Trials
by adah
Jingjing Ye, PhD. BeiGene. PSI Journal Club: Bayes...
Design principles and objectives:
Design principles and objectives:
by catherine
Proposed an efficient exosome-based tumor antigens...
Managing CINV and Cachexia
Managing CINV and Cachexia
by min-jolicoeur
Program Goals. Concepts and Definitions for “Su...
phase ii STUDY designs:
phase ii STUDY designs:
by calandra-battersby
Part 2. Resident and Fellows Lecture Series. A. p...
Novel Strategies in the Management of Progressive
Novel Strategies in the Management of Progressive
by calandra-battersby
BRCA. -Mutated Breast Cancer. This program will i...
Dose finding designs driven by immunotherapy outcomes with Application to a metastatic melanoma pha
Dose finding designs driven by immunotherapy outcomes with Application to a metastatic melanoma pha
by lois-ondreau
Elizabeth Garrett-Mayer, PhD. Cody Chiuzan, MS. H...
Experimental Results for a Novel
Experimental Results for a Novel
by alida-meadow
Microwave. Radiator . Structure Targeting Non-inv...
Clinical Trial Protocol & Amendments
Clinical Trial Protocol & Amendments
by liane-varnes
William Petros, PharmD, FCCP. Professor, Schools ...
Adaptive Population Enrichment for Oncology Trials with Tim
Adaptive Population Enrichment for Oncology Trials with Tim
by giovanna-bartolotta
Cyrus Mehta, Ph.D.. President, Cytel Inc. .. Stat...